Nodal variations and long-term changes in the main tides on the coasts of China

The long-term changes in the main tidal constituents (O1, K1, M2, N2, and S2) along the coasts of China and in adjacent seas are investigated based on 17 tide-gauge records covering the period 1954–2012. The observed 18.61 year nodal modulations of the diurnal constituents O1 and K1 are in agreement with the equilibrium tidal theory, except in the South China Sea. The observed modulations of the M2 and N2 amplitudes are smaller than theoretically predicted at the northern stations and larger at the southern stations. The discrepancies between the theoretically predicted nodal variations and the observations are discussed. The 8.85 year perigean cycle is identifiable in the N2 parameters at most stations, except those in the South China Sea. The radiational component of S2 contributes on average 16% of the observed S2 except in the Gulf of Tonkin, on the south coast, where it accounts for up to 65%. We confirmed the existence of nodal modulation in S2, which is stronger on the north coast. The semidiurnal tidal parameters show significant secular trends in the Bohai and Yellow Seas, on the north coast, and in the Taiwan Strait. The largest increase is found for M2 for which the amplitude increases by 4–7 mm/yr in the Yellow Sea. The potential causes for the linear trends in tidal constants are discussed.

Report [A].

Text in French.

Recüeil de plusieurs relations et traitez singuliers et curieux de J.B. Tavernier ..., qui n'ont point esté mis dans ses six premiers voyages : divisé en cinq paties [sic]

Contiene según consta en portada: I. Une relation du Japon, & de la cause de la persecution des chrestiens dans ses isles ... II. Relation de ce qui s'est passé dans la negociation des deputez qui ont esté en Perse & aux Indes, tant de la part du Roy, que de la Compagnie Françoise, pour l'establissement du commerce. III. Observations sur le commerce des Indes Orientales, & sur les fraudes qui s'y peuvent commettre. IV. Relation nouvelle & singuliere du Royaume de Tunquin ... V. Histoire de la conduite des hollandois en Asie.

Three species of Peromyscus,

Mode of access: Internet.

You're on camera ... in color : a television handbook for extension workers /

"October 1969"--P. [4] of cover.

School of Nursing Class of 1997

Top Row: Shelly Adkins, Nikki Alexadner, Amy L. Ancona, Adem Arslani, Noel Baldwin, Lea Bell, Michelle Bellah, Nicole Bills, Sarah Boyle, Rebekah Brandstatter, Margitt Brigant, Matthew Brooks, Julie Campbell, Lea Clemmons

Row 2: Iracema M. Crawford, Amy Decker, Danielle Terry, Jennifer McGeown, Megan Lindsey Tvaska, Molly McIntyre, Sharon M. Hoover, Mary Beth Pohanka, Jennifer Nelson, Jennifer Carney, Katheryn E. Huffman, Toria Dial, Mary Dooley

Row 3: Pamela Earl, Stacy Ekelman, Jennfier Emery, Robert Farrell, Stephanie R. Faudel, Amy Fischer, Rochelle Fountain, Diane Fox

Row 4: Tina Garcia, Monica Gatica, Meredith Giles, Karla Giminez, Emily Goodsell, Barbara Gurd, Keren Kay Hahn, Beth Hosmer, Shana N. Howard, Cina Jackson-Hanner

Row 5: Kristy Jakubiak, Rebekah Johnson, Stephanie T. Johnson, Jennifer Jorissen, Richard W. Redman, Beverly Jones, Ada Sue Hinshaw, Nola Pender, Susan Boehm, Renee Kaplan, Angela Kendrick-Newing, Emily Kerschbaum, Donulae Knuckles

Row 6: Diane Kramer, Alyce Krause, Krista L. Kuczewski, Lori LaCrone, Melissa E. Lorencen, Sarah Lyons, Melissa Magante, Kathleen Mahon, Christy Mayes, Joseph Morris, Elizabeth Morrow, Tamala Myers, Michele Nextico

Row 7: Jacquelyn Nino, Denise Noto, Catherine Orser, Elizabeth Palad, Ann Peterson, Joshua Pietsch, Pati Putt, Lisa Reinhart, Jamie C. Renken, Amy Robbins, Ernest Saxton, Amy Schafer, Joelle Schroeder, Matthew Seiler

Row 8: Sarah Bellestri Shih, Kristen Sisson, Shalonda Smith, Kathleen Stewart, Jeannine Sutter, Jamie Swan, Arita Ann Sywenkyj, Julie Talbott, Diana Thorrez, Natasha Tokarz, Whitney Tonkin, Rea Tsatsanifos, Tina Urbanski

Row 9: Maricar Uy, Dana Van Singel, Tanya D. Venton, Christina Vitucci, Samuel Walsh, Susan Warren, Tiana Washington, Yvette White, Judy M. Wilson, Cerise Wotorson, Bella Yagolkovskaya, Karen Zalenko, Susan M. Zucal

Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose - Results from the LIPID trial

OBJECTIVE- Diabetes, a major health problem worldwide, increases the risk of cardiovascular disease and its associated mortality. Evidence of the overall benefits of lipid modification in this area is needed. RESEARCH DESIGN AND METHODS- The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) trial showed that cholesterol-lowering treatment with pravastatin reduced mortality and coronary heart disease (CHD) events in 9,014 patients aged 31-75 years with CHD and total cholesterol 4.0-7.0 mmol/l. We measured the effects of pravastatin therapy, 40 mg/day over 6.0 years, on the risk of CHD death or nonfatal myocardial infarction and other cardiovascular outcomes in 1,077 LIPID patients with diabetes and 940 patients with impaired fasting glucose (IFG). RESULTS- in patients allocated to placebo, the risk of a major CHD event was 61% higher in patients with diabetes and 23% higher in the IFG group than in patients with normal fasting glucose, and the risk of any cardiovascular event was 37% higher in the diabetic group and 19% higher in the IFG group. Pravastatin therapy reduced the risk of a major CHD event overall from 15.9 to 12.3% (relative risk reduction [RRR] 24%, P < 0.001) and from 23.4 to 19.6% in the diabetic group (19%, P = 0.11); in the diabetic group, the reduction was not significantly different from the reductions in the other groups. Pravastatin reduced the risk of any cardiovascular event from 52.7 to 45.2% (21%, P < 0.008) in patients With diabetes and from 45.7 to 37.1% (26%, P = 0.003) in the IFG group. Pravastatin reduced the risk of stroke from 9.9 to 6.3% in the diabetic group (RRR 39%, Cl 7-61%, P = 0.02) and from 5.4 to 3.4% in the IFG group (RRR 42%, Cl -9 to 69%, P = 0.09). Pravastatin did not reduce the incidence of diabetes. Over 6 years, pravastatin therapy prevented one major,CHD event (CHD death or nonfatal myocardial infarction) in 23 patients with IFG and 18 patients with diabetes. A meta-analysis of other major trials confirmed the high absolute risks of diabetes and IFG and the absolute benefits of statin therapy in these patients. CONCLUSIONS- Cholesterol-lowering treatment with pravastatin therapy prevents cardiovascular events, including stroke, in patients with diabetes or IFG and established CHD.